Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2024 | The value of mass spectrometry in multiple myeloma & how this may impact clinical practice

Noemí Puig • 7 Oct 2024
IMS 2024
Multiple Myeloma

Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, discusses the advantages of mass spectrometry in assessing M-proteins in multiple myeloma and other monoclonal gammopathies. Dr Puig highlights that mass spectrometry offers higher sensitivity compared to conventional methods and can identify patients with a worse prognosis who may have been missed by traditional testing. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Noemí Puig

Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma 2:17
Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma
Noemí Puig • 18 Sep 2025
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA 3:49
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA
Noemí Puig • 18 Sep 2025
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM 2:20
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM
Noemí Puig • 7 Oct 2024
Standardizing MRD techniques after FDA approval as a surrogate endpoint in myeloma trials 1:18
Standardizing MRD techniques after FDA approval as a surrogate endpoint in myeloma trials
Noemí Puig • 7 Oct 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals